TY  - JOUR
AU  - Clingan, Philip
AU  - Ladwa, Rahul
AU  - Brungs, Daniel
AU  - Harris, Dean Laurence
AU  - McGrath, Margaret
AU  - Arnold, Susan
AU  - Coward, Jermaine
AU  - Fourie, Samuel
AU  - Kurochkin, Andriy
AU  - Malan, Daniel R.
AU  - Mant, Andrew
AU  - Sharma, Vinay
AU  - Shue, Hong
AU  - Tazbirkova, Andrea
AU  - Berciano-Guerrero, Miguel-Angel
AU  - Charoentum, Chaiyut
AU  - Dalle, Stephane
AU  - Dechaphunkul, Arunee
AU  - Dudnichenko, Oleksandr
AU  - Koralewski, Piotr
AU  - Lugowska, Iwona
AU  - Montaudie, Henri
AU  - Munoz-Couselo, Eva
AU  - Sriuranpong, Virote
AU  - Oliviero, James
AU  - Desai, Jayesh
PY  - 2023
DO  - 10.1136/jitc-2023-007637
SN  - 2051-1426
UR  - https://hdl.handle.net/10668/28506
T2  - Journal for ImmunoTheraphy of Cancer
AB  - Programmed cell death receptor-1 (PD-1)-blocking antibodies are approved to treat metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) cases ineligible for curative surgery or radiation. Notwithstanding, some patients experience...
LA  - en
PB  - BMJ Group
KW  - Immunotherapy
KW  - Programmed Cell Death 1 Receptor
KW  - Skin Neoplasms
KW  - Immune Checkpoint Inhibitors
KW  - Carcinoma, Squamous Cell
KW  - Programmed Cell Death 1 Receptor
KW  - Immune Checkpoint Inhibitors
KW  - Response Evaluation Criteria in Solid Tumors
KW  - Follow-Up Studies
KW  - B7-H1 Antigen
KW  - Skin Neoplasms
TI  - Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma
TY  - research article
VL  - 11
ER  -